

U.S.S.N. 09/378,261
Filed: August 20, 1999

CLEAN VERSION OF AMENDED CLAIMS

28. The method of claim 16 wherein the compound is a receptor fragment.
29. The method of claim 16 wherein the compound is combined with a pharmaceutically acceptable carrier.
30. The method of claim 16 wherein the compound is administered in an amount effective to enhance an inflammatory response involving blocking of protein C or activated protein C binding to an endothelial cell protein C/activated protein C receptor.

Clean Version of Amended Claims
Pursuant to 37 C.F.R. § 1.121(c)(1)(ii)

16. (amended) A method for enhancing an inflammatory response involving blocking of protein C or activated protein C binding to an endothelial cell protein C/activated protein C receptor comprising administering to a patient in need of treatment thereof an amount of a compound blocking binding of protein C or activated protein C to the receptor by binding to the endothelial cell protein C/activated protein C receptor.

17. (amended) The method of claim 16 wherein the compound is selected from the group consisting of antibodies and fragments of antibodies to the receptor, and synthetic or natural compounds other than proteins, or peptides which inhibit binding.

24. (amended) A method for enhancing an inflammatory response involving blocking of protein C or activated protein C binding to an endothelial cell protein C/activated protein C receptor comprising administering to a patient in need of treatment thereof an amount of antibody or antibody fragment immunoreactive with the receptor to block binding of protein C or activated protein C to the receptor by binding to the endothelial cell protein C/activated protein C receptor.

25. The method of claim 24 wherein the antibody is humanized.

26. (amended) The method of claim 24 wherein the compound is labeled.

28. The method of claim 16 wherein the compound is a receptor fragment.

U.S.S.N. 09/378,261

Filed: August 20, 1999

CLEAN VERSION OF AMENDED CLAIMS

29. The method of claim 16 wherein the compound is combined with a pharmaceutically acceptable carrier.
30. The method of claim 16 wherein the compound is administered in an amount effective to enhance an inflammatory response involving blocking of protein C or activated protein C binding to an endothelial cell protein C/activated protein C receptor.

ATL1 #552761 v1